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Sum m ary Sulphonylurea derivatives are widely used 
in the treatment of non-insulin-dependent diabetes 
mellitus. The mechanism of action of the insulino- 
tropic effect of these agents is based on the closure 
of adenosine-S'-triphosphate (ATP)-sensitive potas­
sium channels (KATP-channels) in the beta cells of 
the pancreas. In the last decade, these KATP-channels 
have been demonstrated in myocardial cells as well 
as in vascular smooth muscle cells. During myocardi­
al ischaemia, the KATP-channels are thought to open 
by a fall in the cytosolic ATP concentration. The in­
crease in the extracellular adenosine concentration, 
and the release of endothelium-derived hyperpolariz- 
ing factor (EDHF) during ischaemia may further 
contribute to the opening of cardiovascular KAXP- 
channels. Independently from the mechanism of 
opening, sulphonylurea derivatives have been report­
ed to block the opening of cardiovascular KATP-chan- 
nels. Related to the role of KATP-channel~opening in
the (patho)physiology of ischaemia, the use of sul­
phonylurea derivatives significantly modifies the out­
come of experimental myocardial infarction. Sulpho­
nylurea derivatives impair the recovery of the con­
tractile function and increase the ultimate infarct 
size in animal models. In contrast, sulphonylurea de­
rivatives have a beneficial effect on the incidence of 
ventricular fibrillation as occurs after ischaemic inci­
dents of the myocardium. Based on these experimen­
tal observations, human studies are indicated to in­
vestigate whether the use of these drugs modifies the 
clinical outcome of cardiovascular events in patients 
with non-insulin dependent diabetes mellitus. [Dia­
betologia (1995)38:116-121]
Key w ords Sulphonylurea derivatives, potassium 
channels, cardiovascular system, adverse effects, 
ischaemia.
Non-insulin-dependent diabetes mellitus (NIDDM) 
accounts for about 85 % of all cases of diabetes melli­
tus, and has been reported to be an important risk 
factor for cardiovascular morbidity and mortality [1- 
3]. Up to now, oral hypoglycaemic drugs, in particu­
lar sulphonylurea derivatives, have represented the 
backbone of NIDDM therapy for the last decades [4, 
5]. The beneficial metabolic effects of sulphonylurea
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derivatives in NIDDM are thought to be based on 
an augmented release of insulin from the beta cells 
of the pancreas. At the cellular level, sulphonylurea 
derivatives exert their insulinotropic effect by clos­
ing the so-called ATP-dependent potassium chan­
nels. This in turn results in depolarization of the beta 
cell, which promotes an influx of calcium via the 
opening of voltage-dependent calcium-ion channels 
on the beta-cell membrane. The resultant increased 
binding of calcium ions to calmodulin will ultimately 
result in the exocytosis of insulin-containing secreto­
ry granules [4, 5].
Interestingly, several studies have shown that the 
cardiovascular system also shares functional ATP-de- 
pendent potassium channels (KATP-channels) [6, 7]. 
Related to the important role of these channels in
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Fig.1. Schematic presentation of the cel­
lular mechanisms contributing to the 
opening of ATP-dependent potassium 
channels (KATP~channels) during isch­
aemia of the myocardial cell or the vas­
cular smooth muscle cell. These mecha­
nisms respectively are: © ) an ischaemia- 
relatecl fall in the intracellular concentra­
tion of ATP ([ATPJi), © ) the stimulation 
of adenosine receptors by the increase in 
the extracellular adenosine concentration 
([adenosineJJ, and @) the endothelial 
release of endothelium-derived hyperpo- 
larizing factor (EDHF) via the stimula­
tion of purinergic or muscarinic receptors 
at the luminal side of the endothelium. 
Independent from the mechanism of 
opening, sulphonylurea derivatives have 
been reported to be able to close the car­
diovascular KATP-channels
the (patho-)physiological response to myocardial 
ischaemia, sulphonylurea derivatives have been re­
ported to modulate the outcome of ischaemic inci­
dents in several animal models.
A T P - d e p e n d e n t  p o ta s s iu m  c h a n n e ls  in  the ca rd io va s­
cu la r  sy s tem :  Based on the results of patch-clamp 
techniques, and on pharmacological characteristics, 
the family of potassium channels can be divided into 
four basic groups: the voltage-gated, the ion-gated, 
the ligand-gated and the “second messenger/metabo- 
lite”-gated channels [8]. The KATP-channels belong to 
the latter category. Several investigators have illus­
trated the existence of cardiovascular KATP-channels, 
both in the myocardium as well as in vascular 
smooth muscle cells [6, 7]. Opening and closure of 
these KATP-channels is dependent on the cytosolic 
concentration of ATP. U nder physiological condi­
tions these potassium channels are generally in a 
closed dorm ant state [8, 9]. During hypoxia and/or 
ischaemia, the cytosolic concentration of ATP falls 
which directly results in opening of KATP-channels. 
Voltage-clamp studies have shown that the subse­
quent efflux of potassium induces hyperpolarization 
of the cell membrane with shortening of the action 
potential and with a decline in the contractile ampli­
tude of myocardial cells [10]. In vascular smooth mus­
cle cells, opening of KATP~channels and subsequent 
hyperpolarization exerts relaxation of these cells, re­
sulting in an obvious vasodilator response [11].
A part from a lowering effect on the intracellular 
ATP-concentration, ischaemia also results in an in­
crease of the intracellular adenosine concentration 
by the breakdown of ATP. During ischaemia, adeno­
sine leaks out of the cell and stimulates specific mem­
brane receptors of the P r purinergic type, the so- 
called adenosine receptors [12]. Interestingly, a spe­
cific subtype of these adenosine receptors, the A r re- 
ceptors, have been reported to be coupled to KAXP-
channels [13]. Consequently, during ischaemia KATP- 
channels are not only opened directly by lowering 
the cytosolic ATP concentration, but also indirectly 
via adenosine receptor stimulation.
A third way to open KATP-channels during isch­
aemia, may be the production of endothelium-de­
rived hyperpolarizing factor (EDHF). Several stud­
ies have shown the role of the endothelium in the va­
sodilator response to ischaemia. It has been demon­
strated that under ischaemic conditions the endothe­
lium secretes several mediators including acetylcho­
line and ATP [14-16], which are both able to stimu­
late the production of endothelium-derived relaxing 
factors via, respectively, muscarinic and purinergic 
receptors at the luminal side of the endothelium, 
A part from nitric oxide, this receptor stimulation in­
duces the production of endothelium-derived hyper­
polarizing factor (EDHF) [17]. Up to now, the struc­
ture of ED H F has been unknown, but the vasodila­
tor properties are based on hyperpolarization, and it 
has been suggested that this hyperpolarization is 
brought about by stimulation of KATP-channels [18].
During myocardial ischaemia three different 
mechanisms can contribute to the opening of KAXP- 
channels. First, a decrease in intracellular ATP-con­
centration directly opens KAXP-channels. Second, in­
crements in extracellular adenosine concentrations 
as a result of ATP-breakdown may open KATP-chan- 
nels by stimulation of A r adenosine receptors. Third, 
the endothelial release of E D H F during ischaemia 
may also open KAXP-channels. Figure 1 summarizes 
these three mechanisms of KATP-channel-opening 
during ischaemia.
S u lp h o n y lu r e a  d er iva tives  a n d  ca rd iovascu la r  K ATP- 
channels:  Animal experiments have convincingly 
shown that sulphonylurea derivatives are able to in­
teract with cardiovascular K ATP-channels. In vascular 
smooth muscle cells, this has been extensively stud­
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ied by investigating the interaction between sulpho­
nylurea derivatives and K vn,-channel-opening drugs 
[19]. Potassium-channel-opening drugs comprise a 
group of vasodilator substances, including experi­
mental therapeutics such as cromakalini. bimakalim 
and lemakalim, but also classic antihypertensive va­
sodilator drugs such as diazoxide and minoxidil [8]. 
In several animal models, sulphonylurea derivatives 
were able to attenuate the vasodilator response to 
KAT1>-channel-opening drugs [8, 20]. In the majority 
of these studies glibenclamide was used, but in fact 
other investigated sulphonylurea derivatives, such as 
tolbutamide and glipizide also showed this specific in­
teraction, confirming the potency of these hypo- 
glycaemic drugs in closing vascular KATP-channeIs. 
Apart from the interaction of sulphonylurea deriva­
tives with potassium channel-opening drugs, gliben­
clamide has been reported to reduce resting myocar­
dial blood flow [21].
Interestingly, in the dog, glibenclamide was also 
able to reduce the coronary vasodilator response to 
adenosine [22, 23], although the maximal response 
to adenosine was not affected by glibenclamide [23]. 
Since the vasodilator response to adenosine is 
thought to be mediated by the A2-subtype of adeno­
sine receptors, these data suggest that not only the 
myocardial A r adenosine receptors [13], but also the 
vascular A2-adenosine receptors are at least partly 
coupled to KATP-channels. This suggestion is support­
ed by the observation that glibenclamide inhibits the 
vasodepressor response to a selective A2-receptor 
agonist in the anaesthetized dog [24], Apart from the 
interaction with KATP-channel-opening drugs and 
with adenosine, glibenclamide has also been report­
ed to inhibit the vasodilator response to endothe- 
lium-dependent vasodilators such as acetylcholine 
and vasoactive intestinal peptide [7]. Consequently, 
in the vascular smooth muscle cell, all three putative 
mechanisms involved in the opening of KATP-chan- 
nels during ischaemia as illustrated in Figure 1, can 
be inhibited by sulphonylurea derivatives.
Also in the myocardial cell, sulphonylurea deriva­
tives are able to reduce the response to KATP-chan- 
nel-opening. In single canine ventricular myocytes, 
glibenclamide attenuated the prolonging effects of 
the KATP-channel-opener pinacidil on the duration 
of the action potential [25]. Moreover, in the isolated 
canine ventricle, the negative inotropic effects of pin­
acidil were inhibited by glibenclamide in a dose-relat­
ed manner [26]. Glibenclamide was also shown to re­
duce the negative inotropic effects of both adenosine 
and acetylcholine [26], as well as the negative chrono­
tropic effects of adenosine [23].
M yocard ia l ischaem ia and  su lp h o n y lu rea  derivatives: 
During myocardial ischaemia, KATP-channel-open- 
ing may occur as a result of the aforementioned 
three mechanisms (Fig. 1). Animal experiments have
shown that the ischaemia-induced opening of KATP- 
channels plays a role in the protection of the myocar­
dium against ischaemia and reperfusion damage [27], 
In the guinea pig right ventricular wall, pretreatment 
with the KAT1,-channel-opening drug pinacidil aug­
mented the shortening of the action potential in­
duced by no-flow ischaemia, and improved the recov­
ery of mechanical function during reperfusion [27]. In 
contrast, pretreatment with glibenclamide signifi­
cantly prolonged the ischaemia-induced shortening 
of the action potential, and after this pretreatment 
the myocardial preparations failed to recover me­
chanical function [27]. Observations in several other 
animal models have confirmed these results [28-30]. 
Apparently, opening of KATP-channels during isch­
aemia is a physiological and important adaptive 
mechanism for protecting the myocardium when 
blood flow to the tissue is compromised.
Other investigators have demonstrated that the 
vascular smooth muscle cell response to ischaemia is 
also inhibited by glibenclamide [21,22,31]. The post­
occlusive hyperaemic response is reduced after pre­
treatment with sulphonylurea derivatives, and this 
impaired postischaemic hyperaemia may contribute 
to the aforementioned detrimental effects of gliben­
clamide during ischaemia/reperfusion injury. Within 
this context, the phenomenon of “ischaemic precon­
ditioning of the myocardium” seems important. Isch­
aemic preconditioning was firstly described by Mur­
ray et al. [32], and concerns the fact that brief peri­
ods of ischaemia and reperfusion render the myocar­
dium resistant to infarction from a subsequent more 
prolonged coronary occlusion [32], According to the 
literature, adenosine receptors have an important 
role in this phenomenon. Animal experiments have 
convincingly shown that the specific stimulation of 
these receptors by selective adenosine analogues pro­
tects the heart against infarction [33, 34], Moreover, 
prolonging the half-life of endogenously released 
adenosine by specific adenosine uptake inhibitors 
tremendously improved the mortality rate after ex­
perimentally-induced myocardial infarction [35]. 
The mechanism responsible for the protective effect 
of adenosine on the heart is not precisely known, but 
several potential mechanisms of action of adenosine 
have already been shown in man, including its direct 
vasodilator effect [36], its inhibitory effect on plate­
let aggregation [37] and on sympathetic nervous sys­
tem mediated effects [38, 39], and its antiarrhythmic 
properties [40], The putative coupling of A r adeno- 
sine receptors to KATP-channels further emphasizes 
the role of these channels in the pathophysiology of 
myocardial ischaemia, as well as the hypothetical ef­
fects of sulphonylurea derivatives during myocardial 
ischaemia. Indeed, a recent report has suggested that 
activation of KATP-channels is an important mecha­
nism behind the protective effect of ischaemic pre­
conditioning [29]. The observation that glibencla-
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mide abolished the preconditioning effect of the ade- ma concentrations of sulphonylurea derivatives are 
nosine-receptor agonist R-phenyl-isopropyl-adeno- high enough to interact with cardiovascular KATP-
channels during convential therapy. First, the gliben- 
clamide concentrations as mentioned above concern 
peak levels, which of course will persist only for short 
periods after drug administration. Moreover, the con­
centrations which were shown to be effective in 
blocking vascular K ATP-channels [19] are not neces­
sarily high enough to interact with the more impor­
tant myocardial KAXP-channels. In this respect it has 
to be emphasized that differences in the pharmacoki­
netics between the several sulphonylurea derivatives 
have to be taken into account since agents with a rel­
atively short half-life are expected to show shorter 
periods of high plasma levels as compared with 
agents which have much longer half-lives, as for ex­
ample glibenclamide or chlorpropamide [45,46], Fur­
ther, pharmacodynamic studies have shown that high 
dosages may counteract their purpose by reducing 
beta-cell sensitivity to sulphonylurea derivatives 
[47], suggesting that recommendations for therapeu-
sine (R-PIA) further supports the link between myo­
cardial KATP-channels and adenosine-A r receptors 
with respect to the preconditioning phenomenon
[41].
In contrast to the aforementioned observations, 
several investigators have shown beneficial effects of 
glibenclamide during myocardial ischaemia as far as 
the occurrence of ventricular fibrillation is con­
cerned. Shortly following a myocardial infarction 
there is a loss of K+ from the heart, considerably in­
creasing the extracellular K+ concentration. The con­
duction inhomogeneities which result from this K+- 
loss, and the increased likelihood of re-entry as a re­
sult of the shortening of the action potential duration 
probably underlie the occurrence of ventricular fibril­
lation and subsequent mortality within the first hours 
after infarction [42, 43]. Since the ischaemia-related 
K+ efflux is mediated by the opening of K ATP-chan- 
nels, the closure of these channels by sulphonylurea 
derivatives may decrease the occurrence of ventricu­
lar fibrillation during or after ischaemia [42-44],
H y p o th e t ic a l  c lin ica l im p lic a tio n s :  Since diabetes is 
an im portant independent risk factor for the develop­
m ent of atherosclerotic disease, one may assume that 
patients with N ID D M  are relatively often exposed to 
myocardial ischaemia. An im portant fraction of these 
patients is treated with oral sulphonylurea deriva­
tives, and so in these particular subjects the periods 
of myocardial ischaemia or infarction occur in the 
presence of potent KATP-channel-blocking agents 
such as tolbutamide, glibenclamide or glipizide. Be­
cause of the beneficial metabolic effects of sulphonyl­
urea derivatives, the plasma concentrations of these 
drugs are apparently sufficiently high to close K ATP- 
channels in the pancreas. Up to now, there have 
been no arguments to consider these plasma concen­
trations too low to interact with cardiovascular 
KATp-channels. In vitro, glibenclamide concentra-
tic dosages of sulphonylurea derivatives must be low­
er than currently assumed, which again will reduce 
the chance that chronic therapy with these drugs 
may reveal interactions with cardiovascular KATP- 
channels. Within this context of clinical implications, 
it is interesting that a recently developed new sulpho­
nylurea derivative, glimepiride, does not show an in­
teraction with cardiovascular KAXP-channels, this in 
contrast to similar studies with glibenclamide or glipi­
zide [48], In theory, this may lead to a generation of 
pancreas-specific sulphonylurea derivatives.
According to our reasoning, the treatment of 
NIDDM  with glibenclamide or related sulphonyl­
urea derivatives may significantly alter the response 
of the myocardium to ischaemic insults, and as such 
may influence the clinical outcome of myocardial 
ischaemia or infarction. The clinical implications 
may be two-jointed: first, sulphonylurea derivatives 
are thought to worsen the clinical outcome concern­
ing the recovery of the contractile function and con-
tions as low as 0.01 (.imol/1 (~ 5 ng/ml) were able to re- cerning the ultimate infarct size in patients with
duce the vascular relaxation induced by the KATP- 
channel-opening drug pinacidil [19]. In patients with 
NIDDM , treated by glibenclamide, plasma concen-
NIDDM  suffering from a myocardial infarction. Sec­
ond, sulphonylurea derivatives may have a beneficial 
effect on the incidence of ventricular fibrillation com-
trations may reach levels above 300 ng/ml [4], Al- plicating such an acute myocardial infarction. Apart 
though the free drug concentrations are probably from affecting the outcome of myocardial infarction, 
much lower because sulphonylurea derivatives are sulphonylurea derivatives may theoretically also im- 
extensively protein-bound [4], the free plasma con- pair endothelium-dependent vasodilation. Since en- 
cen(rations may still be sufficient to interact with car- dothelial dysfunction is a remarkable feature of coro- 
diovascular KATP-channels. Further, under ischaemic nary artery disease [49], and has even been suggested 
conditions, the production of lactate may lower the to play a causal role in atherosclerosis, sulphonylurea 
regional pH in the interstitium, and interestingly derivatives may have a clinical impact on this level 
such an acidic condition further augments the inhibit­
ing effects of glibenclamide on vascular KATP-chan- It is important to question whether the currently 
nels [17], making low drug concentrations more effec- available clinical and epidemiological knowledge on 
tive. Despite the aforementioned considerations, it the treatm ent of NIDDM  with sulphonylurea deriva- 
remains a critical issue whether or not the free plas- tives argue against our reasoning. Interestingly, the
too.
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UDPG-study observed an increased cardiovascular 
mortality among patients with NIDDM treated by 
tolbutamide versus those treated by diet alone [50]. 
Moreover, smaller studies have also suggested a 
harmful effect of sulphonylurea derivatives on the 
outcome of myocardial infarction [51, 52], In con­
trast, some investigators were not able to confirm 
these observations [53-55], whereas others even sug­
gest reduced cardiovascular complications and an in­
creases survival rate in the tolbutamide-treated 
group as compared with untreated or diet-treated 
groups [56, 57]. An extensive review report on this 
subject suggests that the conclusions of the majority 
of these clinical and epidemiological studies are not 
valid because of important methodological shortcom­
ings or because of a limited statistical power [58], 
Therefore, the currently available data on this item 
do not allow definite conclusions with respect to pos­
sible cardiovascular effects of sulphonylurea deriva­
tives in patients with NIDDM. Especially because of 
the two-jointed character of the aforementioned clin­
ical implications, with detrimental as well as benefi­
cial aspects on the ultimate outcome of myocardial in­
farction, large-scale epidemiological studies will not 
detect such divergent effects as long as the relevant 
end points like ventricular fibrillation and ejection 
fraction are not specifically included. Current knowl­
edge on the role of KATP-channels in the pathophy­
siology of (myocardial) ischaemia emphasizes the 
need for well-controlled epidemiological studies on 
this subject as well as for clinical pharmacological 
studies on the effects of sulphonylurea derivatives on 
KATP-channels in the human cardiovascular system.
Reviews on the use of sulphonylurea derivatives in 
NIDDM report several arguments to recommend the 
use of short-acting agents, at the lowest possible dose 
[46]. Future evaluation of cardiovascular endpoints in 
large-scale clinical trials may uncover whether the in­
teraction with cardiovascular KAXP-channels is anoth­
er reason for this recommendation.
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